The changing role of the CCO in Novartis How did Deliberation change the role of the CCO in Novartis
Keywords
Loading...
Authors
Issue Date
2025-06-30
Language
en
Document type
Journal Title
Journal ISSN
Volume Title
Publisher
Title
ISSN
Volume
Issue
Startpage
Endpage
DOI
Abstract
This research explores how the role of the Chief Compliance Officer (CCO) is evolving in response to increasing ESG compliance, using Novartis as a case study. Its leading position regarding ESG compliance characterises Novartis; therefore, the organisation could provide valuable insights into how organisational ESG compliance has evolved from mere adherence to a holistic compliance culture. Through interviews and document analysis, it examines how deliberation influences the evolution of the CCO role. The findings show that the CCO role, CERCO at Novartis, has gained a substantial position as a holistic compliance executive. Additionally, compliance grew as an essential part of the organisation’s DNA. Deliberation influenced this ongoing evolution, yet its influence is limited due to regulatory constraints. Therefore, has deliberation played a supportive yet limited role in transforming the CCO role within Novartis
Description
Citation
Supervisor
Faculty
Faculteit der Managementwetenschappen